Melena

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ClinicalTrials.gov, Hemoptysis, Proteinuria, Fatal, Recurrence, Hepatocellular carcinoma, Bleeding, Melena, Immunotherapy, PD-L1, Union, Docetaxel, Avascular necrosis, Hypertension, Takeda Pharmaceutical Company, Hematemesis, Fistula, AST, Patient, Pulmonary embolism, ULN, Grade 3, Nivolumab, ONJ, NSCLC, Lung cancer, Venous thrombosis, Sepsis, Post-vaccination embolic and thrombotic events, Roche, Progression-free survival, HIV disease progression rates, Embolism, Nephrotic syndrome, Incidence, ALT, EXEL, VEGFR, Tablet, Survival, History, Sorafenib, DTC, Abscess, HCC, Adrenal insufficiency, Hormone replacement therapy, Perforation, RCC, Ipsen, Risk, Medical imaging, Pharmaceutical industry, Exelixis, Jaw, Takeda

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
  • Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, March 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Research, Liver cancer, Risk, Tablet, DTC, VEGFR, Adrenal insufficiency, EXEL, OS, Union, Proteinuria, Embolism, New Drug Application, Takeda Pharmaceutical Company, Nephrotic syndrome, History, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Melena, ONJ, Hoffmann-La Roche, AST, ALT, Hypertension, Death, Nivolumab, Pulmonary embolism, Fistula, Bleeding, Recurrence, Sepsis, Patient, Perforation, RCC, Nasdaq, Sorafenib, Abscess, Fatal, Avascular necrosis, Hormone replacement therapy, Food, Cancer, Ipsen, Progression-free survival, ClinicalTrials.gov, Hematemesis, Drug discovery, Genentech, HCC, FDA, Adult, Medical Affairs Bureau, ULN, Grade 3, Venous thrombosis, Incidence, Hemoptysis, Post-vaccination embolic and thrombotic events, Pharmaceutical industry, Jaw, Exelixis, COSMIC-312, HCC, CABOMETYX, COSMIC-312, HCC, CABOMETYX

COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.

Key Points: 
  • COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX is not indicated as a treatment for previously untreated advanced HCC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.

Pinnacle West Adds Former Head of Arizona Hispanic Chamber of Commerce to Its Board of Directors

Retrieved on: 
Friday, February 25, 2022
Energy, Other Energy, Utilities, GPL, Enterprise software, Henkel North American Consumer Goods, Arizona State University, Electricity, Thunderbird School of Global Management, PNW, Commerce, National Board of Accountants and Auditors, NYSE, Arizona Public Service, Multimedia, Master of Business Administration, Melena, MBDA, Coca-Cola, AMAC, Thunderbird, Economic development, Business administration, CEO, Minority Business Development Agency, Restaurant, Management, Pinnacle West Capital

For nearly a decade, de la Melena served Arizona communities as President and CEO of the Arizona Hispanic Chamber of Commerce, where he helped Latino-owned businesses find access to capital and resources to help them grow and prosper.

Key Points: 
  • For nearly a decade, de la Melena served Arizona communities as President and CEO of the Arizona Hispanic Chamber of Commerce, where he helped Latino-owned businesses find access to capital and resources to help them grow and prosper.
  • He also was Operator of the Minority Business Development Agency (MBDA), the regions leading advocate representing more than 200,000-plus minority business enterprises.
  • His relationships with Arizona business and Hispanic communities are important qualities that are valued by me and our entire board.
  • Through its principal subsidiary, Arizona Public Service , the company provides retail electricity service to more than 1.3 million Arizona homes and businesses.

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma

Retrieved on: 
Wednesday, January 5, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, ClinicalTrials.gov, MET, Renal cell carcinoma, Bleeding, Cancer, American Cancer Society, AXL, History, Neoplasm, Roche, ICI, Hormone replacement therapy, RCC, Sepsis, Hepatocellular carcinoma, AST, Avascular necrosis, Fistula, Hemoptysis, Hypertension, Progression-free survival, Hematemesis, Population, Takeda Pharmaceutical Company, Embolism, Union, Incidence, ULN, Proteinuria, Nasdaq, RECIST, Post-vaccination embolic and thrombotic events, Kidney cancer, Man, Sorafenib, DTC, Safety, Adrenal insufficiency, ONJ, Patient, HCC, Venous thrombosis, Protein, Perforation, Nephrotic syndrome, Fatal, Risk, Nivolumab, VEGF, Large-cell lung carcinoma, Growth, Tablet, Adult, ALT, Pulmonary embolism, Abscess, VEGFR, Woman, Melena, Grade 3, EXEL, Recurrence, Ipsen, Pharmaceutical industry, Medical imaging, Exelixis, Jaw, RCC, CABOMETYX, RCC, CABOMETYX

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated for metastatic RCC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
  • Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Population, Venous thrombosis, Progression-free survival, Ipsen, Cancer, Lung cancer, Adenocarcinoma, ULN, Avascular necrosis, Squamous cell carcinoma, Sorafenib, Hypertension, Adrenal insufficiency, Takeda Pharmaceutical Company, Grade 3, Post-vaccination embolic and thrombotic events, Recurrence, VEGFR, European Union, Fistula, Disease, Roche, Hematemesis, Proteinuria, RCC, Abscess, Union, Perforation, Nivolumab, Hormone replacement therapy, Immunotherapy, Fatal, HIV disease progression rates, Sepsis, Bleeding, Hepatocellular carcinoma, Woman, Docetaxel, ALT, DTC, Incidence, AST, Hemoptysis, ClinicalTrials.gov, Large-cell lung carcinoma, Melena, History, ONJ, EXEL, NSCLC, Pulmonary embolism, Nephrotic syndrome, Tablet, HCC, Survival, Nasdaq, Patient, Risk, Embolism, Man, Adult, Pharmaceutical industry, Medical imaging, NSCLC, CABOMETYX, NSCLC, CABOMETYX

In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.

Key Points: 
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX is not indicated as a treatment for metastatic NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Retrieved on: 
Wednesday, August 25, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Sepsis, OS, Fatal, Protein, European Union, RCC, HCC, Venous thrombosis, ULN, Avascular necrosis, Grade 3, Bristol Myers Squibb, EXEL, Hypertension, Risk, Perforation, American Cancer Society, Checkmate, Woman, Nephrotic syndrome, VEGF, Union, Adrenal insufficiency, Embolism, ALT, Hormone replacement therapy, Hemoptysis, Man, ORR, History, Sale, Recurrence, Proteinuria, Bleeding, Incidence, Nasdaq, ONJ, Tablet, Takeda Pharmaceutical Company, Fistula, Sorafenib, AST, PFS, Abscess, Progression-free survival, AXL, Growth, Cancer, Hematemesis, Post-vaccination embolic and thrombotic events, Ipsen, Melena, MET, Patient, Pulmonary embolism, Kidney cancer, Nivolumab, Pharmaceutical industry, CheckMate -9ER, RCC, CABOMETYX® (cabozantinib), Exelixis, CHECKMATE -9ER, RCC, CABOMETYX® (CABOZANTINIB), EXELIXIS

The primary efficacy analysis compares the doublet combination regimen of CABOMETYX and OPDIVO versus sunitinib in all randomized patients.

Key Points: 
  • The primary efficacy analysis compares the doublet combination regimen of CABOMETYX and OPDIVO versus sunitinib in all randomized patients.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.